• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Research Brief on Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate (CAS: 1168090-92-3): Recent Advances and Applications

Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate (CAS: 1168090-92-3) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. Recent studies have highlighted its potential as a key intermediate in the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and anti-inflammatory agents. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and therapeutic potential.

One of the most notable advancements in the study of Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate is its role in the synthesis of novel kinase inhibitors. Kinases are critical targets in the treatment of various cancers and inflammatory diseases, and the ability to modulate their activity with high specificity is a major focus of current research. Recent publications have demonstrated that derivatives of this compound exhibit potent inhibitory effects against specific kinases, such as JAK2 and BTK, which are implicated in hematologic malignancies and autoimmune disorders. These findings underscore the compound's potential as a scaffold for the development of next-generation therapeutics.

In addition to its applications in kinase inhibition, Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate has also been investigated for its anti-inflammatory properties. A study published in the Journal of Medicinal Chemistry reported that certain analogs of this compound significantly reduced the production of pro-inflammatory cytokines in vitro, suggesting a potential role in the treatment of chronic inflammatory conditions. The mechanism of action appears to involve the modulation of NF-κB signaling, a key pathway in the regulation of immune responses. These results highlight the compound's dual utility in both oncology and immunology.

The synthesis of Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate and its derivatives has also seen significant improvements in recent years. Advances in catalytic methods, such as palladium-catalyzed cross-coupling reactions, have enabled more efficient and scalable production of this compound. These methodological innovations not only enhance the accessibility of the compound for research purposes but also pave the way for its industrial-scale production. Furthermore, the development of greener synthetic routes, including the use of biodegradable solvents and catalysts, aligns with the growing emphasis on sustainable chemistry in pharmaceutical manufacturing.

Despite these promising developments, challenges remain in the optimization of Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate-based therapeutics. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed to fully realize the compound's clinical potential. Ongoing research is focused on structural modifications to improve these pharmacokinetic properties, as well as on the identification of new biological targets. Collaborative efforts between academia and industry are expected to accelerate the translation of these findings into clinically viable drugs.

In conclusion, Methyl 5-chloroimidazo[1,5-a]pyridine-6-carboxylate (CAS: 1168090-92-3) represents a promising scaffold in medicinal chemistry, with demonstrated applications in kinase inhibition and anti-inflammatory therapy. Recent advancements in its synthesis and biological evaluation have expanded its potential utility, while also highlighting areas for further investigation. As research in this area continues to evolve, this compound is likely to play an increasingly important role in the development of novel therapeutics for a range of diseases.

• 55234-68-9(ethyl 2-chloro-1,5-naphthyridine-3-carboxylate)
• 112695-60-0(1,2-Indolizinedicarboxylic acid, 3-chloro-7-methyl-, dimethyl ester)
• 132209-79-1(Ethyl 2-chloro-1,8-naphthyridine-3-carboxylate)
• 773874-60-5(3-QUINOLINECARBOXYLIC ACID, 2-CHLORO-6-METHYL-, METHYL ESTER)
• 773874-59-2(Methyl 2-chloro-8-methylquinoline-3-carboxylate)
• 2114758-88-0(1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid, 2-chloro-, methyl ester)
• 112671-64-4(Pyrrolo[1,2-a]quinoline-2,3-dicarboxylic acid, 1-chloro-, dimethyl ester)
• 1124194-70-2(Methyl 2-chloro-1,7-naphthyridine-3-carboxylate)
• 16498-85-4(methyl 2-chloroquinoline-3-carboxylate)
• 1402911-36-7(Methyl 5-chloroimidazo[1,2-a]pyridine-8-carboxylate)